Main Catalog

AMCP Web Site

Main Catalog

Found 118

Sort By

Member Free

Non-Member Free

Legal and Regulatory Considerations Impacting Oncology Specialty Pharmacy

Contact Hours: 1 - Laws and regulations at the state and federal level that impact oncology care.

Legislation Oncology

Member Free

Non-Member Free

Perspectives on Providing Value in Oncology: A Panel Discussion

Contact Hours: 1 - Perceptions of value in oncology care vary among stakeholders.

Oncology

Member Free

Non-Member

The Times They Are a-Changin – A Look at Congressional Efforts to Reform the Medicare and Medicaid Prescription Drug Programs

Contact Hours: 1.5. For more than a decade, millions of American seniors have been able to access prescription drugs through market-driven programs.

Medicare and Medicaid Health Care Reform

Member Free

Non-Member

Preventative Treatment for Alzheimer’s Disease and the Future Role of Value-Based Payment Arrangements

Contact Hours: 1.5. The current understanding of Alzheimer’s disease is evolving.

Value-Based Contracting Alzheimer's

Member

Non-Member

Keeping Up with Rare Disease Therapies: Pipeline to Management Solutions Track

Contact Hours: 1 - Over the last several years, payers have increased their focus on the management of rare diseases.

Drug Pipeline Rare Diseases

Member

Non-Member

Value-Based Payment Models: Opportunities to Integrate Pharmacists from a Variety of Practice Settings

Contact Hours: 1 - Shared savings plans can mitigate health care costs, but how do we establish the relationships required for their success?

Value-Based Contracting

Member

Non-Member

The Role of Health Disparities and Social Determinants of Health in Promoting Health and Health Equity

Contact Hours: 1 - Health care disparities are often viewed through the lens of race/ethnicity and socioeconomic status.

Health Disparities Social Determinants

Member

Non-Member

Keeping Up with State Legislators: Legislative Updates and Outlook

Contact Hours: 1 - The COVID-19 pandemic had a significant impact on state legislation and regulation.

Legislation

Member Free

Non-Member

Biosimilars in the United States: Barriers, Solutions, Real-World Evidence, and the Experience of One Health System

Contact Hours: 1.5. As of July 2019, the U.S. Food and Drug Administration (FDA) had approved 25 biosimilar or follow-on biologic products.

Real World Evidence Biosimilars

Member Free

Non-Member Free

Navigating Changes in Clostridioides difficile Prevention and Treatment

Contact Hours: 1. 5 - Clostridioides difficile (C. diff, previously known as Clostridium difficile) infections are a major health care concern.

C. Diff

Main Catalog

Error